![Celecoxib | CAS:169590-42-5 | Selective cyclooxygenase-2 (COX-2) inhibitor | High Purity | Manufacturer BioCrick Celecoxib | CAS:169590-42-5 | Selective cyclooxygenase-2 (COX-2) inhibitor | High Purity | Manufacturer BioCrick](https://www.biocrick.com/media/images/struct/BCC1099.png)
Celecoxib | CAS:169590-42-5 | Selective cyclooxygenase-2 (COX-2) inhibitor | High Purity | Manufacturer BioCrick
![Diclofenac potentiates the antitumor effect of cisplatin in a xenograft mouse model transplanted with cisplatin-resistant cells without enhancing cisplatin-induced nephrotoxicity - ScienceDirect Diclofenac potentiates the antitumor effect of cisplatin in a xenograft mouse model transplanted with cisplatin-resistant cells without enhancing cisplatin-induced nephrotoxicity - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1347436721000380-gr2.jpg)
Diclofenac potentiates the antitumor effect of cisplatin in a xenograft mouse model transplanted with cisplatin-resistant cells without enhancing cisplatin-induced nephrotoxicity - ScienceDirect
![Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo - ScienceDirect Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0014299920304313-fx1.jpg)
Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo - ScienceDirect
![Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library](https://faseb.onlinelibrary.wiley.com/cms/asset/29311d6c-9ff3-48b2-8def-d7709620d1d4/fsb2fj000716fje-fig-0001-m.jpg)
Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB - Niederberger - 2001 - The FASEB Journal - Wiley Online Library
![Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2005/nejm_2005.352.issue-11/nejmoa050405/production/images/img_medium/nejmoa050405_f1.jpeg)
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention | NEJM
![Celecoxib | CAS:169590-42-5 | Selective cyclooxygenase-2 (COX-2) inhibitor | High Purity | Manufacturer BioCrick Celecoxib | CAS:169590-42-5 | Selective cyclooxygenase-2 (COX-2) inhibitor | High Purity | Manufacturer BioCrick](https://www.biocrick.com/media/images/struct3D/BCC1099.png)